ArticleTherapeutic advances in gastroenterology2009
The treatment of irritable bowel syndrome.
Article in Therapeutic advances in gastroenterology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Improvement of irritable bowel syndrome with glucagon like peptide-1 receptor agonists: a systematic review and meta-analysis.Frontiers in endocrinology · 2025Pooled it
- A Clostridia-rich microbiota enhances bile acid excretion in diarrhea-predominant irritable bowel syndrome.The Journal of clinical investigation · 2020Trial
- The impact of abdominal pain on global measures in patients with chronic idiopathic constipation, before and after treatment with linaclotide: a pooled analysis of two randomised, double-blind, placebo-controlled, phase 3 trials.Alimentary pharmacology & therapeutics · 2014Trial
- Diamine Oxidase Supplementation for Histamine Regulation in Constipation-Predominant Irritable Bowel Syndrome: A Case Report.Integrative medicine (Encinitas, Calif.) · 2026Article
- 2025 Seoul Consensus on Clinical Practice Guidelines for Irritable Bowel Syndrome.Journal of neurogastroenterology and motility · 2025Review
- Diagnosis and treatment of post-cholecystectomy diarrhoea.World journal of gastrointestinal surgery · 2023Review
- Capecitabine-Induced Enterocolitis.Cureus · 2022Article
- Neurotransmitter Dysfunction in Irritable Bowel Syndrome: Emerging Approaches for Management.Journal of clinical medicine · 2021Review
- (Poly)phenols in Inflammatory Bowel Disease and Irritable Bowel Syndrome: A Review.Molecules (Basel, Switzerland) · 2021Review
- Development and validation of the Health Promoting Behaviour for Bloating (HPB-Bloat) scale.PeerJ · 2021Article
- Psychological profiles of irritable bowel syndrome patients with different phenotypes.Intestinal research · 2020Article
- Critical evaluation of animal models of visceral pain for therapeutics development: A focus on irritable bowel syndrome.Neurogastroenterology and motility · 2020Review
- Gut microbiome composition and risk factors in a large cross-sectional IBS cohort.BMJ open gastroenterology · 2020Article
- Observational Study on Knowledge and Eating Habits with Respect to Low- and High-FODMAP Foods in Medical Checkup Populations in Japan.Nutrients · 2019Observational
- Antioxidant Capacity and Behavioral Relevance of a Polyphenolic Extract ofOxidative medicine and cellular longevity · 2019Article
- NaV1.1 inhibition can reduce visceral hypersensitivity.JCI insight · 2018Article
- Clinical Practice Guidelines for Irritable Bowel Syndrome in Korea, 2017 Revised Edition.Journal of neurogastroenterology and motility · 2018Review
- Irritable bowel syndrome diagnosis and management: A simplified algorithm for clinical practice.United European gastroenterology journal · 2017Review
- Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome: A Bridge between Functional Organic Dichotomy.Gut and liver · 2017Review
- Pathogenesis, Experimental Models and Contemporary Pharmacotherapy of Irritable Bowel Syndrome: Story About the Brain-Gut Axis.Current neuropharmacology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Irritable bowel syndrome (IBS) is a highly prevalent functional bowel disorder routinely encountered by healthcare providers. Although not life-threatening, this chronic disorder reduces patients' quality of life and imposes a significant economic burden to the healthcare system. IBS is no longer considered a diagnosis of exclusion that can only be made after performing a battery of expensive diagnostic tests. Rather, IBS should be confidently diagnosed in the clinic at the time of the first visit using the Rome III criteria and a careful history and physical examination. Treatment options for IBS have increased in number in the past decade and clinicians should not be limited to using only fiber supplements and smooth muscle relaxants. Although all patients with IBS have symptoms of abdominal pain and disordered defecation, treatment needs to be individualized and should focus on the predominant symptom. This paper will review therapeutic options for the treatment of IBS using a tailored approach based on the predominant symptom. Abdominal pain, bloating, constipation and diarrhea are the four main symptoms that can be addressed using a combination of dietary interventions and medications. Treatment options include probiotics, antibiotics, tricyclic antidepressants, selective serotonin reuptake inhibitors and agents that modulate chloride channels and serotonin. Each class of agent will be reviewed using the latest data from the literature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.